DNA vaccine development company Inovio Pharmaceuticals (AMEX:INO) announced Monday the appointment of Angel Cabrera to the company’s board of directors.
"Inovio is honored to have Dr. Cabrera, a world renowned
international business expert, bring his unique management and
leadership experience to Inovio's Board,” said Inovio’s president and
CEO, Dr. J. Joseph Kim.
"His insights will be valuable to Inovio's organizational development
and in the strategic decision-making around the many technology and
product development as well as partnering opportunities available to us
as we advance our synthetic vaccines."
Dr. Cabrera is the outgoing president of the Thunderbird School of
Global Management, and will become president of George Mason University,
the largest university in Virginia, on July 1, 2012.
During his eight-year reign at the Thunderbird school, Dr. Cabrera
led an academic, operational and financial overhaul, stemming operating
deficits and declining revenues.
Prior to this, Cabrera served as Dean at the IE Business School in
Madrid, which he helped transform into a highly ranked international
Dr. Cabrera has published in fields ranging from learning technology
to psychology, management and higher education, with his most recent
book published by Harvard Business Review Press.
is focused on the discovery, development and delivery of DNA vaccines.
The company is looking at immunotherapies to potentially prevent and
treat cancers and chronic infectious diseases.
Its SynCon vaccines are designed to provide universal cross-strain
protection against known and newly emergent unmatched strains of
The synthetic vaccines, combined with Inovio's proprietary
electroporation delivery, have been shown to generate "best-in-class"
immune responses in humans, the company said, with a favorable safety
Inovio's clinical programs include phase II studies for cervical
dysplasia, leukemia and hepatitis C virus, and phase I studies for
influenza and HIV.
Last month, the company said its SynCon avian flu vaccine generated
protective antibody responses against six different H5N1 virus strains
in a phase I trial, a key step in the company's path to develop
universal flu vaccines.
The company said that with the robust antibody and T cell responses generated, it has achieved proof of principle.
By design, Inovio's SynCon flu vaccine is not matched to any single
virus. The company's SynCon technology allows it to design synthetic
vaccines with the potential to protect against unmatched sub-types and
strains of pathogens, including newly emergent, unknown strains of a
virus that will periodically emerge through mutation, as in the case of